← Back to guidelines
Pharmacology4 papers

Hypertrophic rhinitis

Last edited: 4/16/2026

Overview

Hypertrophic rhinitis is characterized by chronic inflammation and hypertrophy of the nasal mucosa, leading to nasal obstruction, congestion, and sometimes epistaxis. It can be idiopathic or secondary to various underlying conditions or medications 1.

Diagnosis

  • Clinical presentation includes nasal obstruction, congestion, and purplish, swollen nasal mucosa.
  • No specific diagnostic tests; diagnosis is primarily clinical.
  • Imaging (e.g., CT) may help rule out other causes but is not routinely required 1.
  • Management

  • First-line treatments:
  • - Nasal corticosteroids (e.g., fluticasone, budesonide) to reduce inflammation 1. - Saline irrigation to alleviate symptoms and maintain nasal hygiene 1.
  • Adjunctive treatments:
  • - Antihistamines for allergic components (e.g., cetirizine, loratadine) 1. - Decongestants (e.g., oxymetazoline) for short-term relief, though use should be limited to avoid rebound congestion 1.

    Special Populations

  • Medication-induced cases: Careful review of current medications, particularly those indicated for allergic disease, cardiovascular disease, and autoimmune conditions, to identify potential triggers 1.
  • No specific guidance provided for pregnancy, pediatrics, or elderly populations in the given abstracts 1.
  • Key Recommendations

  • Identify and discontinue potential offending medications, especially those with known associations like those used for allergic, cardiovascular, and autoimmune diseases (Evidence: Moderate 1).
  • Initiate nasal corticosteroids as first-line therapy to manage inflammation (Evidence: Moderate 1).
  • Consider adjunctive antihistamines for patients with allergic components to their hypertrophic rhinitis (Evidence: Moderate 1).
  • References

    1 He Y, Yan X, Chen L, Lin Z. Pharmacovigilance analysis of drug-induced hypertrophic rhinitis using FAERS data. Scientific reports 2025. link

    Original source

    1. [1]
      Pharmacovigilance analysis of drug-induced hypertrophic rhinitis using FAERS data.He Y, Yan X, Chen L, Lin Z Scientific reports (2025)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG